B8-1 - The Invention of Samuraciclib, a Highly Selective CDK-7 Inhibitor, the Formation of Carrick Therapeutics and Clinical Trials on Treating Patients with Resistant Cancers

Image carousel

[E] CARRICK THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF ITS ORAL CDK7 INHIBITOR: CT7001 [F] New cancer drug class unveiled at Imperial [G] CT7001, a Novel Orally Bio-Available CDK7 Inhibitor, Is Highly Active in in-Vitro and in-Vivo Models of AML [H] New drug class unveiled at Imperial [I] Evotec Partnered Drug Discovery and Development

Identity area

Reference code

UoA 8-B8-1

Title

The Invention of Samuraciclib, a Highly Selective CDK-7 Inhibitor, the Formation of Carrick Therapeutics and Clinical Trials on Treating Patients with Resistant Cancers

Date(s)

Level of description

Extent and medium

Context area

Archival history

Immediate source of acquisition or transfer

Content and structure area

Scope and content

Appraisal, destruction and scheduling

Accruals

System of arrangement

Conditions of access and use area

Conditions governing access

Conditions governing reproduction

Language of material

Script of material

Language and script notes

Physical characteristics and technical requirements

Finding aids

Allied materials area

Existence and location of originals

Existence and location of copies

Related units of description

Related descriptions

Notes area

Alternative identifier(s)

Access points

Subject access points

Place access points

Name access points

Genre access points

Description control area

Description identifier

Institution identifier

Rules and/or conventions used

Status

Level of detail

Dates of creation revision deletion

Language(s)

Script(s)

Sources

Accession area